PLCB4

Across TCGA pan-cancer cohorts, PLCB4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLCB4 data layer compared with 24 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLCB4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLCB4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PLCB4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.492	0.272	<.001	98	view →
CCRCC	DFS	Median	III,IV	0.735	0.983	.006	31	view →
LUAD	DFS	Tertile	All	0.871	0.991	.011	12	view →
UCEC	DFS	Quartile	All	1.000	0.860	.039	4	view →
LSCC	DFS	Tertile	III,IV	1.000	0.516	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLCB4–PDAC (OS)

Open the PDAC breakdown →